Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.
Bocket L, Peytavin G, Alidjinou EK, Ajana F, Choisy P, Lê M, Charpentier C, Descamps D, Yazdanpanah Y, Katlama C, Simon A, Calvez V, Marcelin AG, Soulie C. Bocket L, et al. Among authors: marcelin ag. J Antimicrob Chemother. 2016 Sep;71(9):2651-3. doi: 10.1093/jac/dkw167. Epub 2016 May 27. J Antimicrob Chemother. 2016. PMID: 27234463
HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.
Recordon-Pinson P, Raymond S, Bellecave P, Marcelin AG, Soulie C, Descamps D, Calvez V, Harrigan PR, Fleury H, Izopet J, Masquelier B; S AC11 Resistance Study Group. Recordon-Pinson P, et al. Among authors: marcelin ag. Antimicrob Agents Chemother. 2013 Feb;57(2):930-5. doi: 10.1128/AAC.02159-12. Epub 2012 Dec 3. Antimicrob Agents Chemother. 2013. PMID: 23208718 Free PMC article.
Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study.
Clavel C, Peytavin G, Tubiana R, Soulié C, Courbon E, Crenn-Hebert C, Ichou H, Blanc C, Schneider L, Katlama C, Marcelin AG, Mandelbrot L. Clavel C, et al. Among authors: marcelin ag. Antimicrob Agents Chemother. 2012 Jul;56(7):4018-20. doi: 10.1128/AAC.06474-11. Epub 2012 Apr 23. Antimicrob Agents Chemother. 2012. PMID: 22526321 Free PMC article.
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
Lambert-Niclot S, Charpentier C, Storto A, Fofana DB, Soulié C, Fourati S, Visseaux B, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG. Lambert-Niclot S, et al. Among authors: marcelin ag. J Antimicrob Chemother. 2013 Jun;68(6):1237-42. doi: 10.1093/jac/dkt003. Epub 2013 Jan 29. J Antimicrob Chemother. 2013. PMID: 23361642
Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study.
Seang S, Fourati S, Keita Y, Blanc C, Tubiana R, Schneider L, Valantin MA, Caby F, Calin R, Lambert-Niclot S, Marcelin AG, Calvez V, Costagliola D, Katlama C. Seang S, et al. Among authors: marcelin ag. J Antimicrob Chemother. 2014 Dec;69(12):3356-9. doi: 10.1093/jac/dku265. Epub 2014 Jul 22. J Antimicrob Chemother. 2014. PMID: 25056835
Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.
Lambert-Niclot S, Allavena C, Grude M, Flandre P, Sayon S, Andre E, Wirden M, Rodallec A, Jovelin T, Katlama C, Calvez V, Raffi F, Marcelin AG. Lambert-Niclot S, et al. Among authors: marcelin ag. J Antimicrob Chemother. 2016 Aug;71(8):2248-51. doi: 10.1093/jac/dkw146. Epub 2016 May 26. J Antimicrob Chemother. 2016. PMID: 27231280
Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia.
Katlama C, Soulié C, Caby F, Denis A, Blanc C, Schneider L, Valantin MA, Tubiana R, Kirstetter M, Valdenassi E, Nguyen T, Peytavin G, Calvez V, Marcelin AG. Katlama C, et al. Among authors: marcelin ag. J Antimicrob Chemother. 2016 Sep;71(9):2646-50. doi: 10.1093/jac/dkw186. Epub 2016 Jun 10. J Antimicrob Chemother. 2016. PMID: 27287235
Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations.
Palich R, Wirden M, Peytavin G, Lê MP, Seang S, Abdi B, Schneider L, Tubiana R, Valantin MA, Paccoud O, Soulié C, Calvez V, Katlama C, Marcelin AG. Palich R, et al. Among authors: marcelin ag. J Antimicrob Chemother. 2020 Oct 1;75(10):2981-2985. doi: 10.1093/jac/dkaa273. J Antimicrob Chemother. 2020. PMID: 32642769
GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.
Bossi P, Peytavin G, Ait-Mohand H, Delaugerre C, Ktorza N, Paris L, Bonmarchand M, Cacace R, David DJ, Simon A, Lamotte C, Marcelin AG, Calvez V, Bricaire F, Costagliola D, Katlama C. Bossi P, et al. Among authors: marcelin ag. HIV Med. 2004 Sep;5(5):352-9. doi: 10.1111/j.1468-1293.2004.00234.x. HIV Med. 2004. PMID: 15369510 Free article. Clinical Trial.
469 results